Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Abbott Healthcare Products B.V.

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome

Phase 3

Completed

Conditions: Hyperlipidemia Combined

First Posted Date: 2006-07-06

Last Posted Date: 2007-09-03

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 181

Registration Number: NCT00349284

Locations: 🇧🇪
Site 113, Charleroi, Belgium
🇧🇪
Site 112, Couillet, Belgium
🇧🇪
Site 115, Dessel, Belgium

and more 40 locations

Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes

Phase 2

Completed

Conditions: Dyslipidemia/Glucose Metabolism Disorder

First Posted Date: 2006-07-06

Last Posted Date: 2007-09-03

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 382

Registration Number: NCT00349128

Locations: 🇵🇱
Site 201, Katowice, Poland
🇵🇱
Site 203, Katowice, Poland
🇵🇱
Site 202, Warszawa, Poland

and more 48 locations

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

Phase 3

Completed

Conditions: Schizophrenia and Schizoaffective Disorder

Interventions: Drug: Aripiprazole
Drug: Olanzapine
Drug: Risperidone
Drug: Quetiapine
Drug: Ziprasidone

First Posted Date: 2006-07-04

Last Posted Date: 2008-05-21

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 286

Registration Number: NCT00347425

Locations: 🇺🇸
Site 148, Birmingham, Alabama, United States
🇺🇸
Site 194, Little Rock, Arkansas, United States
🇺🇸
Site 178, Anaheim, California, United States

and more 119 locations

Annual Study to Investigate Inactivated Subunit Influenza Vaccine for the 2006/2007 Influenza Season in Europe.

Phase 3

Completed

Conditions: Healthy Volunteers

First Posted Date: 2006-06-30

Last Posted Date: 2009-01-30

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT00346723

Locations: 🇧🇪
Site 1, Tessenderlo, Belgium

Annual Study to Investigate Inactivated Virosomal Influenza Vaccine for the 2006/2007 Influenza Season in Europe.

Phase 3

Withdrawn

Conditions: Healthy Volunteers

First Posted Date: 2006-06-28

Last Posted Date: 2010-02-08

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT00345462

Locations: 🇩🇪
Site 1, Berlin, Germany

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Phase 3

Completed

Conditions: Early Stage Parkinson's Disease

Interventions: Drug: Pardoprunox

First Posted Date: 2006-06-09

Last Posted Date: 2009-02-06

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 202

Registration Number: NCT00335374

Locations: 🇺🇸
419, Birmingham, Alabama, United States
🇺🇸
413, Oceanside, California, United States
🇺🇸
408, Oxnard, California, United States

and more 72 locations

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

Phase 3

Completed

Conditions: Early Stage Parkinson Disease

Interventions: Drug: Pardaprunox
Drug: pramipexole
Drug: Placebo Comparator

First Posted Date: 2006-06-09

Last Posted Date: 2008-04-03

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 330

Registration Number: NCT00335166

Locations: 🇺🇸
419, Birmingham, Alabama, United States
🇺🇸
413, Oceanside, California, United States
🇺🇸
408, Oxnard, California, United States

and more 86 locations

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

Phase 3

Completed

Conditions: Early Stage Parkinson's Disease

Interventions: Drug: Pardoprunox

First Posted Date: 2006-06-02

Last Posted Date: 2009-01-26

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 224

Registration Number: NCT00332917

Locations: 🇺🇸
Site 284, Huntsville, Alabama, United States
🇺🇸
Site 274, Little Rock, Arkansas, United States
🇺🇸
Site 283, Fountain Valley, California, United States

and more 127 locations

Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China

Phase 3

Completed

Conditions: Healthy

First Posted Date: 2006-05-12

Last Posted Date: 2006-11-01

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 900

Registration Number: NCT00325260

Locations: 🇨🇳
Site 1, Nanjing, China

SLV308 for Treatment of Patients With Early Parkinson's Disease

Phase 3

Completed

Conditions: Early Stage Parkinson's Disease

Interventions: Drug: Pardoprunox
Drug: Placebo

First Posted Date: 2005-12-23

Last Posted Date: 2008-08-29

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 468

Registration Number: NCT00269516

Locations: 🇺🇸
Site 284, Huntsville, Alabama, United States
🇺🇸
Site 274, Little Rock, Arkansas, United States
🇺🇸
Site 283, Fountain Valley, California, United States

and more 125 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy